v3.25.2
Members' Deficit (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2023
Dec. 31, 2022
May 31, 2022
Apr. 30, 2021
Jun. 11, 2018
May 20, 2018
Class A Member Units                
Members' Deficit                
Units issued         8,400,000     10,000,000
Value of units issued         $ 4.2     $ 0.1
Units purchased             16,666,666  
Exercise price             $ 0.01  
Value of units exercised           $ 0.2    
Price per unit         $ 0.5      
Remaining percentage of allocation of annual revenue and expenses on a pro rata basis 49.00% 49.00%            
Remaining percentage of allocation of voting interest on pro rata basis 49.00% 49.00%            
Remaining percentage of allocation of liquidation value on pro rata basis 49.00% 49.00%            
Class A Member Units | Valetudo Loan                
Members' Deficit                
Units repurchased       1,400,000        
Repurchase value       $ 0.7        
Repurchase price per unit       $ 0.5        
Class A Member Units | Metavagen LLC ("Metavagen") | Metavagen License Agreement                
Members' Deficit                
Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker       40,000,000        
Number of member units terminated post termination of license rights     40,000,000          
Class A Member Units | Curis Biotech Holdings LLC | CD47 License agreement with InnoBation                
Members' Deficit                
Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker     78,555,554          
Class B Member Units                
Members' Deficit                
Percentage of allocation of annual revenue and expenses 51.00% 51.00%            
Percentage of voting interest 51.00% 51.00%            
Percentage of allocation of liquidation value 51.00% 51.00%